Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2700 participants
OBSERVATIONAL
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying quality of life in patients with bladder cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Enhancing Shared Decision-Making in Metastatic Breast Cancer (Qualitative Study)
NCT03248258
Quality of Life of Older Patients Who Are Undergoing Treatment for Cancer and of Their Family Caregivers
NCT00255697
Study to Assess Cancer Patients' Satisfaction With Hospital Quality of Care
NCT00045019
Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers
NCT00684801
Assessment of the Quality and Sexual Health Needs of Patients with Advanced-stage Cancer
NCT06229158
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To study the effects of recurrence and progression on health-related quality of life (HRQL).
* To study the effects of repeat cystoscopy on HRQL.
* To study the patients' assessments of a hypothetical prognostic model and how this affects their preference for the mode of surveillance.
OUTLINE: This is a multicenter study.
Quality-of-life questionnaires developed by the European Organization for Research and Treatment for Cancer (EORTC) will be used. The EORTC QLQ-BLS24 with 24 questions specific to non-muscle-invasive bladder cancer and the EORTC QLQ-BLM30 with 30 questions specific to muscle-invasive bladder cancer will be combined and used in conjunction with the general cancer questionnaire QLQ-C30.
Assessments using the QLQ-C30 will be made at baseline in the entire cohort of patients. Follow-up assessments using the QLQ-C30, QLQ-BLS24, and QLQ-BLM30 167 will be made at first routine follow-up and annually until the end of study.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
quality-of-life assessment
questionnaire administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Bladder lesion with cystoscopic characteristics compatible with urothelial cancer or transitional cell carcinoma meeting 1 of the following criteria:
* Non-muscle-invasive tumor
* Muscle-invasive tumor
* Solitary G1 pTa tumor
* Fit for cystoscopy and surgical biopsy/resection
Exclusion Criteria
PATIENT CHARACTERISTICS:
* HIV infection
* Any condition that, in the opinion of the local investigator, might interfere with the safety of the patient or evaluation of the study objectives
PRIOR CONCURRENT THERAPY:
* Not specified
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Birmingham
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maurice Zeegers, MD
Role: STUDY_CHAIR
University of Birmingham
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Birmingham
Birmingham, England, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Maurice Zeegers, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRUK-BCPP-2005-01-QOL
Identifier Type: -
Identifier Source: secondary_id
ISRCTN13889738
Identifier Type: -
Identifier Source: secondary_id
EU-20768
Identifier Type: -
Identifier Source: secondary_id
CDR0000574081
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.